HEPNET

Serial Number 97855612
Registration 7575493
700

Registration Progress

Application Filed
Mar 24, 2023
Under Examination
May 7, 2024
Approved for Publication
Feb 21, 2024
Published for Opposition
Mar 12, 2024
Registered
Nov 26, 2024

Trademark Image

HEPNET

Basic Information

Serial Number
97855612
Registration Number
7575493
Filing Date
March 24, 2023
Registration Date
November 26, 2024
Published for Opposition
March 12, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 26, 2024
Registration
Registered
Classes
005 009 040 042

Rights Holder

E-Therapeutics Plc

99
Address
Floor 4B
4 Kingdom Street, Paddington Central
London W26BD
GB

Ownership History

E-Therapeutics Plc

Original Applicant
99
London GB

E-Therapeutics Plc

Owner at Publication
99
London GB

E-Therapeutics Plc

Original Registrant
99
London GB

Legal Representation

Attorney
Anna King

USPTO Deadlines

Next Deadline
1844 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-26)
Due Date
November 26, 2030
Grace Period Ends
May 26, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

30 events
Date Code Type Description Documents
Nov 26, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Nov 26, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 5, 2024 DP1B I 1(B) BASIS DELETED; PROCEED TO REGISTRATION Loading...
Nov 4, 2024 D1BR I TEAS DELETE 1(B) BASIS RECEIVED Loading...
Nov 4, 2024 IUCN S NOTICE OF ALLOWANCE CANCELLED Loading...
May 7, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 12, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 12, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Feb 21, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 21, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 2, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 30, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 30, 2024 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Jan 30, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 30, 2024 GPRN O NOTIFICATION OF PRIORITY ACTION E-MAILED Loading...
Jan 30, 2024 GPRA O PRIORITY ACTION E-MAILED Loading...
Jan 30, 2024 CPRA R PRIORITY ACTION WRITTEN Loading...
Dec 26, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 26, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 26, 2023 ALIE A ASSIGNED TO LIE Loading...
Jul 31, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
May 18, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 18, 2023 GNRT O NON-FINAL ACTION E-MAILED Loading...
May 18, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 27, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 27, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 27, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 25, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 16, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 28, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
Class 009
Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery
Class 040
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
Class 042
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid

Classification

International Classes
005 009 040 042